Astria Therapeutics, Inc.

Industry

  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies

Other Names/Subsidiaries

  • Catabasis Pharmaceuticals
  • Quellis Biosciences
See more in Biomedtracker

Latest on Astria Therapeutics, Inc.

Scrip

Deal Watch: Revance To Go Private In Crown Laboratories Buyout

 
• By Joseph Haas and Vibha Ravi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Crown Will Offer $924m To Merge With Re

Scrip

IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf

 
• By Anju Ghangurde

Ichnos Glenmark Innovation (IGI) believes its first-in-class T cell-engaging trispecific antibody has what it takes to make a mark in multiple myeloma (MM) , a segment dominated by big pharma players

Scrip

Finance Watch: Alto, Fractyl Bring IPO Count To Four, So Far, In 2024

 
• By Mandy Jackson

The number of biopharma initial public offerings in the US in 2024 grew to four with IPOs by Alto Neuroscience Inc. and Fractyl Health , showing that investors continue to be supportive of certain

Scrip

Deal Watch: Lilly Will Take Over Beam’s Rights To Verve Cardiovascular Assets

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With Verve Again By Acqu